CHEPLAPHARM Arzneimittel GmbH


This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.


Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit


The latest from CHEPLAPHARM

CHEPLAPHARM invests 6 million euros in the expansion of its German headquarters in Greifswald – funded by own sources only

From August 2018, CHEPLAPHARM expands its Ziegelhof headquarters in the Hanseatic city of Greifswald with a new building on an area of 5,300 square meters. The extension with state-of-the-art office facilities will be completed by the end of 2019. As a result, the pharmaceutical company has enough space for a total of 250 employees on approximately 8,000 square meters.

"CHEPLAPHARM has been continuously and significantly growing for years. Thus, today and in the future, we want to make sure to offer our highly qualified employees optimally equipped office and work spaces here in Greifswald, where we feel very comfortable," reasons Sebastian F. Braun (CEO) the extensive construction project. This is a clear commitment to the location Greifswald.

As with comparable previous construction projects, CHEPLAPHARM realizes the extension with the help of local companies and finances the necessary investments of about 6 million euros entirely without public subsidies.

In addition, CHEPLAPHARM follows the guidelines for a careful use of resources and energy efficiency when planning new buildings. For example, charging stations for e-cars and e-bikes on the newly constructed area will be installed. Furthermore, there will be state-of-the-art conference rooms in the new building, that can be adapted to different requirements: from internal meetings of smaller groups to larger groups of up to 30 people. The meeting rooms will also be equipped with state-of-the-art presentation technology and innovative communication media.

The approximately 213 square meters large roof terrace can be used for events as well as - due to the connection to the social rooms – for socializing during the lunch break or after work.

NDR Media Center: Arzneimittel aus Mesekenhagen bei Greifswald

Press Office:
CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse(at)

Investor Relations topics

Back to top expand_less